Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs

(2014) Luca Semerano et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1  Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression

(2014) T. Nishikawa et al.   JOURNAL OF IMMUNOLOGY

Predictive Factors of Response to Biological Disease Modifying Antirheumatic Drugs: Towards Personalized Medicine

(2014) Claire I. Daïen et al.   MEDIATORS OF INFLAMMATION

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis

(2014) Toshihisa Kojima et al.   Modern Rheumatology

IL-6 in Inflammation, Immunity, and Disease

(2014) T. Tanaka et al.   Cold Spring Harbor Perspectives in Biology

Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis – focus on subcutaneous tocilizumab

(2014) Yasuharu Nakashima et al.   Drug Design Development and Therapy

Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome-Wide DNA Microarray

(2014) Yoshie Sanayama et al.   Arthritis & Rheumatology

Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy

(2013) Naoshi Nishina et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

(2013) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis

(2013) Bernard Bannwarth et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis

(2013) Xiaoping Zhang et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)

(2013) Shuji Ohta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Tocilizumab versus adalimumab for rheumatoid arthritis

(2013) Salvatore De Vita   LANCET

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases

(2013) Yasuaki Okuda et al.   Modern Rheumatology

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

(2013) Atsushi Ogata et al.   ARTHRITIS CARE & RESEARCH

Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients

(2013) Soken-Nakazawa J Song et al.   ARTHRITIS RESEARCH & THERAPY

Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review

(2013) Al-Shakarchi et al.   Patient Preference and Adherence

IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis

(2013) Jianmei Wang et al.   BMJ Open

Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study

(2012) Stephanie Finzel et al.   ANNALS OF THE RHEUMATIC DISEASES

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis

(2012) César Faillace et al.   RHEUMATOLOGY INTERNATIONAL

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Disease–Drug–Drug Interaction Involving Tocilizumab and Simvastatin in Patients With Rheumatoid Arthritis

(2011) C Schmitt et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis

(2011) Xiaoping Zhang et al.   Expert Review of Clinical Pharmacology

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease

(2010) S.-N. J. Song et al.   BLOOD

Clinical safety of tocilizumab in rheumatoid arthritis

(2010) Bernard Bannwarth et al.   Expert Opinion On Drug Safety

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview

(2009) J. A. Singh et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial

(2008) Shumpei Yokota et al.   LANCET